Research advances in high-risk paraneoplastic antibody-associated neurological disorders
10.19845/j.cnki.zfysjjbzz.2026.0049
- VernacularTitle:高危副肿瘤抗体相关神经系统疾病的研究进展
- Author:
Yuxuan ZHOU
1
;
Weihong LIN
1
Author Information
1. Department of Neurology， The First Hospital of Jilin University， Changchun 130021， China
- Publication Type:Journal Article
- Keywords:
Paraneoplastic neurologic syndromes;
High-risk paraneoplastic antibodies;
Immune checkpoint inhibitors;
Autoimmunity
- From:
Journal of Apoplexy and Nervous Diseases
2026;43(3):280-288
- CountryChina
- Language:Chinese
-
Abstract:
Paraneoplastic neurologic syndromes （PNS） are immune-mediated disorders of the nervous system triggered by cross-immune response induced by tumor-associated antigens. Since high-risk paraneoplastic antibodies are highy associated with malignancies， they have an important clinical value in the early recognition， tumor screening， and prognostic assessment of PNS. The diagnostic criteria updated in 2021 further refined the classification of high-risk antibodies and clarified their value in risk assessment. This article systematically reviews the clinical spectrum， tumor associations， and immunopathogenic mechanisms of neurological disorders associated with the high-risk paraneoplastic antibodies such as anti-Hu， anti-Ri， anti-CV2， anti-Ma2， anti-amphiphysin， anti-Yo， anti-PCA2， anti-Tr， anti-SOX1， and anti-KLHL11 antibodies. Immunotherapy combined with active control of primary tumor is the main treatment strategy for such disease， but with a limited overall therapeutic effect， and early identification is of particular importance. In the era of the wide application of immune checkpoint inhibitors （ICIs）， the risk of ICIs in inducing or exacerbating should be taken seriously in clinical practice. Mechanistic research， multimodal diagnostic approaches， and individualized treatment strategies should be enhanced in the future to improve the prognosis of patients.
- Full text:2026061211032884193高危副肿瘤抗体相关神经系统疾病的研究进展.pdf
